kabutan

Noile-Immune Biotech Inc.(4893) Summary

4893
TSE Growth
Noile-Immune Biotech Inc.
180
JPY
+9
(+5.26%)
Mar 13, 3:30 pm JST
1.12
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
182
Mar 13, 11:57 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.99
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:03 am
163 JPY 1.02 USD
Previous Close Mar 12
171 JPY 1.07 USD
High Mar 13, 2:51 pm
184 JPY 1.15 USD
Low Mar 13, 9:05 am
160 JPY 1.00 USD
Volume
2,847,800
Trading Value
0.50B JPY 3.11M USD
VWAP
174.24 JPY 1.09 USD
Minimum Trading Value
18,000 JPY 112 USD
Market Cap
7.79B JPY 0.05B USD
Number of Trades
1,455
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
233
1-Year High Jul 2, 2025
8,956
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 1,015,800 1,215,600 1.20
Feb 27, 2026 766,300 1,172,600 1.53
Feb 20, 2026 649,800 1,180,400 1.82
Feb 13, 2026 487,400 1,228,300 2.52
Feb 6, 2026 330,700 968,100 2.93
Company Profile
Noile-Immune Biotech Inc. engages in the development of novel immunotherapies utilizing CAR-T cells for cancer treatment.
Sector
Pharmaceuticals
Noile-Immune Biotech Inc. focuses on developing novel immunotherapies utilizing CAR-T cells for cancer treatment. The company aims to develop effective CAR-T cell therapies for solid tumors using its proprietary PRIME technology. PRIME technology is a platform technology that can be applied to regenerative medicine, with the potential to achieve superior cancer treatment effects by activating immune cells within the patient's body. It promotes the infiltration and activation of immune cells into solid tumor tissues. Noile-Immune Biotech pursues two business models: in-house drug discovery and collaborative pipelines, with multiple pipelines in progress. The company is also conducting clinical trials targeting solid tumors, exploring new possibilities in cancer immunotherapy.